The Guardian
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker’s new chief executive Luke Miels announces one of its biggest deals Business live – latest updates GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn)…
View original source — The Guardian ↗
Related stories
Financial Times
HealthJun 9, 2026 · 1 min
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
Financial Times
Bloomberg
HealthJun 9, 2026 · 1 min
GSK Agrees to Buy Nuvalent for $10.6 Billion
Bloomberg
MarketWatch
HealthJun 9, 2026 · 1 min
GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down
MarketWatch
Bloomberg
HealthJun 9, 2026 · 1 min
GSK in Talks to Buy Nuvalent for More Than $9 Billion: FT
Bloomberg